FMP

FMP

Enter

VRPX - Virpax Pharmaceutica...

Financial Summary of Virpax Pharmaceuticals, Inc.(VRPX), Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-deli

photo-url-https://financialmodelingprep.com/image-stock/VRPX.png

Virpax Pharmaceuticals, Inc.

VRPX

NASDAQ

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

0.523 USD

0.0116 (2.22%)

About

ceo

Dr. Sheila A. Mathias J.D., M.B.A., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.virpaxpharma.com

exchange

NASDAQ

Description

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company...

CIK

0001708331

ISIN

US9282511073

CUSIP

928251107

Address

1055 Westlakes Drive

Phone

610 727 4597

Country

US

Employee

7

IPO Date

Feb 17, 2021

Summary

CIK

0001708331

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

928251107

ISIN

US9282511073

Country

US

Price

0.52

Beta

1.23

Volume Avg.

156.13k

Market Cap

1.43M

Shares

-

52-Week

0.4603-11.77

DCF

7.81

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.04

P/B

-

Website

https://www.virpaxpharma.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest VRPX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep